Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioma 3Glioblastoma 3Colorectal Neoplasms 2Astrocytoma 2Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1Bone Neoplasms 1

Interventions

Carboplatin 9pembrolizumab 8Paclitaxel 8Cisplatin 8Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6Gemcitabine 5fludarabine 4Specimen Handling 4Pemetrexed 4Nivolumab 4Cyclophosphamide 4trebananib 3osimertinib 3liposomal doxorubicin 3Radiotherapy 3Interleukin-2 3Fluorouracil 3Docetaxel 3DNA 3volociximab 2poly ICLC 2lenvatinib 2fludarabine phosphate 2Sorafenib 2Radiosurgery 2Midazolam 2Capecitabine 2Biopsy 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma × lentiviral minigene vaccine of COVID-19 coronavirus × Clear all
NCT01671592 2017-09-26

Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)

University of Pittsburgh

Phase 1 Completed
6 enrolled
Gastrointestinal

Carcinoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡